Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +62

Boston Trust Walden Corp Decreases Stock Position in Charles River ...

AI-generated analysis

📉 Boston Trust Walden Corp decreased its CRL position by 6.4%, selling 19,452 shares in Q1 2026.

📈 Invesco Ltd. significantly increased its holdings by 115.8% to own 2,696,150 shares valued at $537.8 million.

🚀 Victory Capital Management Inc. boosted its stake by 9,938.8%, acquiring an additional 684,586 shares.

📊 Morgan Stanley upgraded CRL to 'overweight' and raised the price target from $185 to $220.

🔼 CLSA upgraded the stock to 'outperform' with a new price target of $219.00.

💰 Director James C. Foster sold 75,000 shares for $16.875 million under a Rule 10b5-1 plan.

📉 The stock trades at a negative P/E ratio of -61.33 with a market cap of $11.11 billion.

🏦 Institutional investors own 98.91% of the company's total outstanding shares.

🎯 The consensus analyst price target is $215.88 based on twelve Buy ratings and three Hold ratings.

Bullish Signals
  • Multiple major investment banks have upgraded their ratings or raised price targets, indicating strong institutional confidence in the company's growth prospects.
  • Invesco Ltd. has aggressively increased its position by over 100%, signaling a bullish view on the stock's future performance.
  • Victory Capital Management Inc. and Ameriprise Financial Inc. have also substantially increased their stakes, adding significant institutional buying pressure.
  • The company maintains a strong balance sheet with a quick ratio of 1.03 and a current ratio of 1.36.
Risk Factors
  • Director James C. Foster executed a large sale of 75,000 shares, representing a 70.36% decrease in his personal ownership stake.
  • The stock currently trades at a negative P/E ratio of -61.33, reflecting recent earnings challenges or losses.
Full Analysis
Institutional investors have made significant adjustments to their positions in Charles River Laboratories International (CRL) during the first quarter of 2026. Boston Trust Walden Corp reduced its stake by 6.4%, selling 19,452 shares and holding a remaining position valued at $49.2 million. Conversely, several other major funds increased their holdings, with Invesco Ltd. growing its position by 115.8% to own over 2.6 million shares valued at $537.8 million, while Victory Capital Management Inc. saw a massive percentage increase in its stake. Analyst sentiment remains largely positive for the medical research company, with multiple major firms upgrading ratings or raising price targets. Morgan Stanley upgraded CRL to an 'overweight' rating and lifted its price objective to $220. Similarly, CLSA moved to an 'outperform' rating with a $219 target, and Barclays increased its target to $220. The consensus average rating is currently a 'Moderate Buy' with a collective price target of $215.88. Corporate insider activity includes a notable sale by Director James C. Foster, who sold 75,000 shares for approximately $16.9 million under a pre-arranged trading plan, reducing his personal ownership to roughly 31,596 shares. Despite this insider reduction, hedge funds and institutional investors collectively own 98.91% of the company's outstanding stock. The firm continues to operate as a leading provider of research models and services for the pharmaceutical and biotechnology industries.